GlaxoSmithKline plc logo
GlaxoSmithKline plc GSK
$ 50.38 -1.02%

Annual report 2025
added 04-18-2026

report update icon

GlaxoSmithKline plc Financial Ratios 2011-2026 | GSK

Annual Financial Ratios GlaxoSmithKline plc

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

- - - - 40.5 13.5 19.1 23.1 46.3 75.9 8.6 28.0 16.9 17.9 15.7

P/S

- - - - 8.4 3.2 2.6 2.7 2.3 2.5 3.0 3.4 3.5 3.1 3.0

EPS

- - - - 0.9 1.2 0.9 0.7 0.3 0.2 1.7 - - - -

EV (Enterprise Value)

41.8 B 42.5 B 43.3 B 46.3 B 260 B 131 B 145 B 134 B 14.1 B 35.8 B 55.2 B 70.1 B 91.2 B 77.3 B 81 B

EBITDA per Share

- - - - 1.24 3.15 2.81 2.23 1.67 3.21 1.76 2.41 3.03 3.1 3.44

EV/EBITDA

33.1 13.1 11.0 8.6 9.7 10.2 18.8 15.3 14.7 12.7 11.3

PEG

- -5.48 0.64 1.43 5.68 -14.99 -0.85 0.04 -0.57 0.8 -1.6 0.07

P/B

- - - - 9.7 3.7 4.8 22.8 0.6 13.9 8.2 15.6 11.7 12.1 9.4

P/CF

- - - - 26.0 9.2 11.1 9.9 10.2 22.9 149.3 30.9 22.7 39.2 23.0

ROE %

- - - - - 27.63 25.30 98.67 43.91 18.38 94.86 55.83 69.59 67.66 59.60

ROA %

- - - - 6.44 7.15 5.83 6.24 2.72 1.54 15.76 6.78 12.92 11.01 12.81

ROCE %

- - - - - 13.35 -36.78 -19.42 -17.90 7.72 3.93 7.98 10.59 11.15 12.87

Current Ratio

1.4 1.3 1.3 1.2 1.4 1.3 1.3 1.1 -1.1 -0.9 -1.2 -1.1 -1.1 -1.0 -1.1

DSO

- - - - 0.0 0.0 0.0 0.1 0.1 - - - - - -

DIO

- - - - - - - - - 200.5 194.4 210.9 165.8 183.5 192.8

Operating Cycle

- - - - 0.0 0.0 0.0 0.1 0.1 200.5 194.4 210.9 165.8 183.5 192.8

Cash Conversion Cycle

- - - - 0.0 0.0 0.0 0.1 0.1 200.5 194.4 210.9 165.8 183.5 192.8

All numbers in GBP currency

Quarterly Financial Ratios GlaxoSmithKline plc

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Current Ratio

- - - - 1.4 - - - 1.4 - - - 1.3 - - - 1.1 - - - 1.1 - - - 1.1 - - - - - - - - - - - - - - - - - - - - - - -

All numbers in GBP currency

Multiples are an important financial analysis tool for the company GlaxoSmithKline plc, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
BioNTech SE BioNTech SE
BNTX
$ 95.5 -3.88 % $ 27.2 B germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 22.35 0.72 % $ 3.7 B usaUSA
Galapagos NV Galapagos NV
GLPG
$ 28.39 -0.13 % $ 2.69 B belgiumBelgium
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.27 0.49 % $ 6.83 B spainSpain
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.5 5.42 % $ 5.76 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.97 -7.51 % $ 152 M germanyGermany
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.42 -0.3 % $ 2.98 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 1.4 -2.1 % $ 235 M franceFrance
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 52.38 -2.24 % $ 4.71 B schweizSchweiz
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.64 4.46 % $ 436 M britainBritain
Inventiva S.A. Inventiva S.A.
IVA
$ 5.42 2.85 % $ 138 M franceFrance
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA